Zenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare Deal

The biggest news this week has been Zenas BioPharma, Inc.'s (NASDAQ: ZBIO ) licensing agreement with InnoCare ( OTCPK:INCPF ). It's a deal tipped to be worth $2 billion, with Zenas gaining rights to the global market, onlyI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciati ...